SV2A Antibody

Code CSB-PA117413
Size US$166
Order now
Image
  • The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA117413(SV2A Antibody) at dilution 1/25, on the right is treated with synthetic peptide. (Original magnification: ×200)
  • The image on the left is immunohistochemistry of paraffin-embedded Human lung cancer tissue using CSB-PA117413(SV2A Antibody) at dilution 1/25, on the right is treated with synthetic peptide. (Original magnification: ×200)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
KIAA0736 antibody; OTTHUMP00000014065 antibody; SV2 antibody; Sv2a antibody; SV2A_HUMAN antibody; Synaptic vesicle glycoprotein 2 antibody; Synaptic vesicle glycoprotein 2A antibody; Synaptic vesicle protein 2a antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Synthetic peptide of Human SV2A
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:2000-1:5000
IHC 1:25-1:100
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles.; (Microbial infection) Receptor for the C.botulinum neurotoxin type A2 (BoNT/A, botA); glycosylation is not essential but enhances the interaction. Probably also serves as a receptor for the closely related C.botulinum neurotoxin type A1.
Gene References into Functions
  1. Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines. PMID: 26339411
  2. SV2A expression in the bladder urothelium increases after BoNT-A injection. PMID: 26241848
  3. the way LEV analogues may interact with SV2A PMID: 25692762
  4. agents that act on the conformation of SV2A might hold great potential in the search for new SV2A-based anticonvulsant therapies PMID: 23530581
  5. The newly identified galactose transport capability of SV2A may have an important role in regulating/modulating synaptic function. PMID: 25326386
  6. The SV2A/FE65 interaction might play a role in synaptic signal transduction. PMID: 24284412
  7. In classical mesial temporal sclerosis 1A, the expression of SV2 isoforms is altered with a marked decrease of SV2A paralleling synaptic loss. PMID: 23617838
  8. High SV2A expression is associated with breast cancer. PMID: 23244111
  9. This study in the German population provides evidence, at a genetic level, for the involvement of the SV2A gene region in schizophrenia. PMID: 23017826
  10. Data report a combined modelling and mutagenesis study that successfully identifies another 11 residues in synaptic vesicle protein 2A that appear to be involved in ligand binding. PMID: 21936812
  11. expression of SV2A in tumor and peritumoral tissue is correlated to the clinical response to levetiracetam and predicts levetiracetam efficacy PMID: 21795655
  12. the role of SV2A in epileptogenesis in patients with glial tumors is questionable PMID: 20167814
  13. We found no association between genetic variation in SV2A and response to levetiracetam or epilepsy predisposition PMID: 18977120
  14. The pattern of SV2A immunoreactivity with reduced neuropil expression and altered cellular and subcellular distribution suggests a possible contribution of SV2A to the epileptogenicity of these malformations of cortical development. PMID: 19220410
  15. Botulinum toxin type A (BTA) inhibits the growth of LNCaP human PCa cells in vitro and in vivo. BTA acts on the cells by virtue of the BTA receptor, the SV2 protein. PMID: 19399787

Show More

Hide All

Subcellular Location
Cell junction, synapse, presynapse. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane; Multi-pass membrane protein.
Protein Families
Major facilitator superfamily
Database Links

HGNC: 20566

OMIM: 185860

KEGG: hsa:9900

STRING: 9606.ENSP00000358142

UniGene: Hs.516153

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*